Earnings Call Summary | VolitionRX(VNRX.US) Q1 2024 Earnings Conference
Earnings Call Summary | VolitionRX(VNRX.US) Q1 2024 Earnings Conference
The following is a summary of the VolitionRx Limited (VNRX) Q1 2024 Earnings Call Transcript:
以下是VolitionRX Limited（VNRX）2024年第一季度财报电话会议记录的摘要：
Financial Performance:
财务业绩：
VolitionRx reported Q1 revenue of approximately $170,000, a 15% increase compared to the same period last year, mainly generated from Nu.Q Vet operations.
The company finished the first quarter with cash/cash equivalents of approximately $11.8 million.
A goal to become cash flow neutral by 2025 has been set, through the reduction of expenditure by $10 million annually, revenue growth, and procuring non-dilutive funding and licensing payments from Nu.Q NET and Capture-PCR.
VolitionRx公布的第一季度收入约为17万美元，与去年同期相比增长了15％，主要来自Nu.Q Vet的业务。
该公司在第一季度结束时现金/现金等价物约为1180万美元。
通过每年减少1000万美元的支出、收入增长以及从Nu.Q NET和Capture-PCR获得非稀释性资金和许可付款，已经设定了到2025年实现现金流中立的目标。
Business Progress:
业务进展：
The company has made significant headway with the Nu.Q NET, Capture-PCR, and Nu.Q lung cancer technologies.
VolitionRx expects to complete data in two key areas, Nu.Q NET and Capture-PCR by next month, potentially leading to royalties and milestone payments within a year.
Progress continues in lung cancer studies, and successful results are soon to be released.
In veterinary operations, the rollout of the Nu.Q Vet canine test continues in the U.S., Europe, and Japan. Feedback has been positive.
Expansion into sepsis diagnosis shows significant progress, with plans to introduce a sepsis product under a licensing model.
The company intends to expand the application of their Capture-PCR test in the broader biopharma R&D market.
Preliminary discussions to extend the use of the Nu.Q Vet for monitoring purposes to veterinarians have begun.
Cost-saving measures are in place, including executive salary cuts, with a goal to reduce operating costs by $10 million in the next year.
该公司在Nu.Q NET、Capture-PCR和Nu.Q肺癌技术方面取得了重大进展。
VolitionRx预计将在下个月之前完成两个关键领域的数据，即Nu.Q NET和Capture-PCR，这有可能在一年内获得特许权使用费和里程碑式的支付。
肺癌研究继续取得进展，不久将公布成功结果。
在兽医业务中，Nu.Q Vet犬类测试继续在美国、欧洲和日本推出。反馈是积极的。
扩展到败血症诊断领域取得了重大进展，计划在许可模式下推出败血症产品。
该公司打算扩大其捕获聚合酶链反应测试在更广泛的生物制药研发市场的应用。
关于将Nu.Q Vet用于监测目的的使用范围扩大到兽医的初步讨论已经开始。
已经采取了节省成本的措施，包括削减高管薪水，目标是在明年将运营成本降低1000万美元。
More details: VolitionRX IR
更多详情： VolitionRX 红外
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。